Xencor (XNCR) Net Equity Issued and Repurchased (2013 - 2018)
Xencor (XNCR) posted quarterly Net Equity Issued and Repurchased of $260.2 million for Q1 2018, up 111.74% quarter-over-quarter from $122.9 million in Q1 2015.
Powered by 
Analysis
Xencor (XNCR) Net Equity Issued and Repurchased (2013 - 2018) Analysis & Trends
Xencor (XNCR) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $260.2 million the latest figure, recorded in Q1 2018.
- In Q1 2018, Net Equity Issued and Repurchased changed N/A year-over-year to $260.2 million; the TTM figure through Dec 2018 stood at $260.2 million (changed N/A YoY), while the FY2024 annual figure was $201.3 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased advanced to $260.2 million in Q1 2018 per XNCR's latest filing, from $122.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $260.2 million in Q1 2018 and bottomed at $122.9 million in Q1 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | 260.25 Mn |
| Mar 31, 2015 | 122.91 Mn |
| Dec 31, 2013 | 70.52 Mn |
| Sep 30, 2013 | 2.40 Mn |
| Jun 30, 2013 | 10.00 Mn |